Cargando…

Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR

Here we compared clonotype identification by allele-specific oligonucleotide real-time quantitative-PCR (ASO RQ-PCR) and next-generation sequencing (NGS) in 80 multiple myeloma patients. ASO RQ-PCR was applicable in 49/55 (89%) and NGS in 62/78 (80%). Clonotypes identified by both methods were ident...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Qiumei, Bai, Yinlei, Kumar, Shaji, Au, Elaine, Orfao, Alberto, Chim, Chor Sang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878533/ https://www.ncbi.nlm.nih.gov/pubmed/33585233 http://dx.doi.org/10.3389/fonc.2020.611021

Ejemplares similares

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma
por: Yao, Qiumei, et al.
Publicado: (2019)

High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes
por: Bai, Yinlei, et al.
Publicado: (2016)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

“Friends and foes” of multiple myeloma measurable/minimal residual disease evaluation by next generation flow
por: Pacelli, Paola, et al.
Publicado: (2022)

Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy
por: Ferla, Valeria, et al.
Publicado: (2022)

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020)

Distinct promoter methylation profile reveals spatial epigenetic heterogeneity in 2 myeloma patients with multifocal extramedullary relapses
por: Yao, Qiumei, et al.
Publicado: (2018)

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
por: Flores-Montero, J, et al.
Publicado: (2017)

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020)

Editorial: Circulating molecular biomarkers: next-generation tools for monitoring minimal residual disease in cancer patients
por: Amoozgar, Zohreh, et al.
Publicado: (2023)

Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches
por: Kostopoulos, Ioannis V., et al.
Publicado: (2020)

Minimal residual disease negativity by next‐generation flow in non‐CR myeloma patients
por: Kim, Sung‐Min, et al.
Publicado: (2020)

Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma
por: Kim, Hyun-Young, et al.
Publicado: (2022)

Clinical implication of minimal residual disease assessment by next-generation sequencing-based immunoglobulin clonality assay in pediatric B-acute lymphoblastic leukemia
por: Lee, Jae Wook, et al.
Publicado: (2022)

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives
por: Romano, Alessandra, et al.
Publicado: (2019)

Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?
por: Bolli, Niccolo, et al.
Publicado: (2020)

Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma
por: Wong, Kwan Yeung, et al.
Publicado: (2018)

Use of Minimal Residual Disease Status to Reduce Uncertainty in Estimating Long-term Survival Outcomes for Newly Diagnosed Multiple Myeloma Patients
por: van Hest, Naomi, et al.
Publicado: (2023)

Case series: MRD negativity assessment using (11)C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma
por: Ngai, Cheong, et al.
Publicado: (2021)

Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
por: Fonseca, Rodrigo, et al.
Publicado: (2023)

Dynamics of Minimal Residual Disease in Neuroblastoma Patients
por: Uemura, Suguru, et al.
Publicado: (2019)

Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: impact on prognosis and myeloma dissemination
por: Li, Zhenhai, et al.
Publicado: (2020)

The role of the bone microenvironment in regulating myeloma residual disease and treatment
por: Dadzie, Terry G., et al.
Publicado: (2022)

Liquid biopsies and minimal residual disease in myeloid malignancies
por: Allam, Sabine, et al.
Publicado: (2023)

Liquid biopsies and minimal residual disease in lymphoid malignancies
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
por: Fonseca, Rodrigo, et al.
Publicado: (2023)

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
por: Anderson, Kenneth C., et al.
Publicado: (2021)

Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients
por: Chim, Chor Sang
Publicado: (2010)

Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA
por: Diefenbach, Russell J., et al.
Publicado: (2022)

P908: FACTORS ASSOCIATED WITH THE CLINICAL PROGNOSTIC PERFORMANCE OF MINIMAL RESIDUAL DISEASE ASSESSMENT BY NEXT GENERATION FLOW CYTOMETRY IN MULTIPLE MYELOMA
por: Nandakumar, B., et al.
Publicado: (2022)

Detection of minimal residual disease by next generation sequencing in AL amyloidosis
por: Sarosiek, Shayna, et al.
Publicado: (2021)

Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis
por: Palladini, Giovanni, et al.
Publicado: (2021)

Minimal residual disease in multiple myeloma: are we there yet?
por: Devarakonda, Srinivas, et al.
Publicado: (2020)

Minimal residual disease in multiple myeloma: current status
por: Ding, Hong, et al.
Publicado: (2021)

Drug resistance and minimal residual disease in multiple myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
por: Della Starza, Irene, et al.
Publicado: (2019)

Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
por: Del Giudice, Ilaria, et al.
Publicado: (2019)

Epigenetic liquid biopsies for minimal residual disease, what’s around the corner?
por: Johnston, Andrew D., et al.
Publicado: (2023)

Editorial: Minimally-invasive treatment for genitourinary cancers: what comes next?
por: Chierigo, Francesco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4r6einfb3pn0hp13bnssdrhdb9